Skin physiological parameters confirm the therapeutic efficacy of pimecrolimus cream 1% in patients with mild-to-moderate atopic dermatitis

Experimental Dermatology

Volumn 18, Issue 1, 2009, Pages 24-29

  Aschoff, Roland ^a   Schwanebeck, Uta ^a   Bräutigam, Matthias ^b   Meurer, Michael ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b NOVARTIS PHARMA GMBH   (Germany)

Author keywords

Atopic dermatitis; Elidel; Pimecrolimus; Skin physiological parameter

Indexed keywords

EMOLLIENT AGENT; HYDROCORTISONE ACETATE; PIMECROLIMUS; PLACEBO;

ADULT; ANGINA PECTORIS; ARTICLE; ATOPIC DERMATITIS; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CREAM; DERMATITIS SEVERITY INDEX; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FLU LIKE SYNDROME; HUMAN; HYDRATION; INVESTIGATORS GLOBAL ASSESSMENT; MALE; MICROCIRCULATION; RANDOMIZED CONTROLLED TRIAL; SKIN INFLAMMATION; SKIN WATER LOSS; VIRAL CONJUNCTIVITIS; VISUAL ANALOG SCALE;

ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; DERMATOLOGY; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PLACEBOS; SKIN; TACROLIMUS; TREATMENT OUTCOME;

EID: 57649232762     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/j.1600-0625.2008.00756.x     Document Type: Article

References (41)

1. Eichenfield L F, Lucky A W, Boguniewicz M et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 2002: 46: 495-504.
2. Kaufmann R, Fölster-Holst R, Höger P et al. Onset of action of pimecrolimus cream 1% in the treatment of atopic eczema in infants. J Allergy Clin Immunol 2004: 114: 1183-1188.
3. Ho V C, Gupta A, Kaufmann R et al. Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. J Pediatr 2003: 142: 155-162.
4. Murrell D F, Calvieri S, Ortonne J P et al. A randomized controlled trial of pimecrolimus cream 1% in adolescents and adults with head and neck atopic dermatitis and intolerant of, or dependent on, topical corticosteroids. Br J Dermatol 2007: 157: 954-959.
5. Wahn U, Bos J D, Goodfield M et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002: 110: 1-8.
6. Meurer M, Fölster-Holst R, Wozel G, Weidinger G, Jünger M, Bräutigam M. Pimecrolimus cream in the long-term management of atopic dermatitis in adults: A six-month study. Dermatology 2002: 205: 271-277.
7. Kapp A, Papp K, Bingham A et al. Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. J Allergy Clin Immunol 2002: 110: 277-284.
8. Grassberger M, Baumruker T, Enz A et al. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: In vitro pharmacology. Br J Dermatol 1999: 141: 264-273.
9. Grassberger M, Steinhoff M, Schneider D, Luger T. Pimecrolimus - an anti-inflammatory drug targeting the skin. Exp Dermatol 2004: 13: 721-730.
10. Stuetz A, Baumann K, Grassberger M, Wolff J, Meingassner J G. Discovery of topical calcineurin inhibitors and pharmacological profile of pimecrolimus. Int Arch Allergy Immunol 2006: 141: 199-212.
11. Büchau A S, Schauber J, Au N, Stuetz A, Gallo R L. Pimecrolimus enhances innate immune function of normal human keratinocytes (conference abstract). J Invest Dermatol 2007: 127: S130 (abstract 777).
12. Cork M, Robinson D, Vasilopoulos Y, Ferguson A. Interaction of topical corticosteroids and pimecrolimus with the skin barrier: Implications for efficacy and safety of treatment for atopic dermatitis. J Am Acad Dermatol 2006: 54(Suppl. 3): AB3.
13. Cork M J, Varghese J, Hadcraft J et al. Differences in the effect of topical corticosteroids and calcineurin inhibitors on the skin barrier - implications for therapy (conference abstract). J Invest Dermatol 2007: 127: S45(abstract 269).
14. Jensen J, Pfeiffer S, Witt M, Elias P M, Fölster-Holst R, Proksch F. Pimecrolimus but not betamethasone treatment improves stratum corneum barrier structure in atopic dermatitis (conference abstract). J Invest Dermatol 2007: 127: S55(abstract 328).
15. Kim D W, Park J Y, Na G Y, Lee S J, Lee W J. Correlation of clinical features and skin barrier function in adolescent and adult patients with atopic dermatitis. Int J Dermatol 2006: 45: 698-701.
16. Fluhr J W, Feingold K R, Elias P M. Transepidermal water loss reflects permeability barrier status: Validation in human and rodent in vivo and ex vivo models. Exp Dermatol 2006: 15: 483-492.
17. Hanifin J M, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol Suppl (Stockholm) 1980: 92: 44-77.
18. Berardesca E, Leveque J L, Masson P. EEMCO guidance for the measurement of skin microcirculation. Skin Pharmacol Appl Skin Physiol 2002: 15: 442-456.
19. Fullerton A, Stücker M, Wilhelm K P. Guidelines for visualization of cutaneous blood flow by laser Doppler perfusion imaging. Contact Dermatitis 2002: 46: 129-140.
20. Rogiers V. EEMCO guidance for the assessment of transepidermal water loss in cosmetic sciences. Skin Pharmacol Appl Skin Physiol 2001: 14: 117-128.
21. Berardesca E. EEMCO guidance for the assessment of stratum corneum hydration: Electrical methods. Skin Res Technol 1997: 3: 126-133.
22. Quinn A G, McLelland J, Essex T, Farr P M. Measurement of cutaneous inflammatory reactions using a scanning laser-Doppler velocimeter. Br J Dermatol 1991: 125: 30-37.
23. Van Leent E J M, Gräber M, Thurston M, Wagenaar A, Spuls P I, Bos J D. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis. Arch Dermatol 1998: 134: 805-809.
24. White M I, McEwan Jenkinson D, Lloyd D H. The effect of washing on the thickness of the stratum corneum in normal and atopic individuals. Br J Dermatol 1987: 116: 525-530.
25. Werner Y, Lindberg M. Transepidermal water loss in dry and clinically normal skin in patients with atopic dermatitis. Acta Derm Venereol 1985: 65: 102-105.
26. Ogawa H, Yoshiike T. Atopic dermatitis: Studies of skin permeability and effectiveness of topical PUVA treatment. Pediatr Dermatol 1992: 9: 383-385.
27. Cork M J, Robinson D, Vasilopoulos Y et al. Predisposition to sensitive skin and atopic eczema. Community Pract 2005: 78: 440-442.
28. Melnik B, Hollman J, Erler E, Verhoeven B, Plewig G. Microanalytical thin layer chromatography of all major stratum corneum lipids. J Invest Dermatol 1989: 92: 231-234.
29. Lavker R M, Schechter N M, Lazarus G S. Effects of TCS on human dermis. Br J Dermatol 1986: 115(Suppl. 31): 101-107.
30. Macheleidt O, Kaiser H W, Sandhoff K. Deficiency of epidermal protein-bound omega-hydroxyceramides in atopic dermatitis. J Invest Dermatol 2002: 119: 166-173.
31. Hara J, Higuchi K, Okamoto R, Kawashima Y, Imokawa G. High expression of sphingomyelin deacylase is an important determinant of ceramide deficiency leading to barrier disruption in atopic dermatitis. J Invest Dermatol 2000: 115: 406-413.
32. Palmer C N, Irvine A D, Terron-Kwiatkowski A et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 2006: 38: 441-446.
33. Candi E, Schmidt R, Melino G. The cornified envelope: A model of cell death in the skin. Nat Rev Mol Cell Biol 2005: 6: 328-340.
34. Rawlings A V, Harding C R. Moisturization and skin barrier function. Dermatol Ther 2004: 17: 43-48.
35. Jakasa I, Verberk M M, Bunge A L, Kruse J, Kezic S. Increased permeability for polyethylene glycols through skin compromised by sodium lauryl sulphate. Exp Dermatol 2006: 15: 801-807.
36. Hudson T J. Skin barrier function and allergic risk. Nat Genet 2006: 38: 399-400.
37. Strid J, Strobel S. Skin barrier dysfunction and systemic sensitization to allergens through the skin. Curr Drug Targets Inflamm Allergy 2005: 4: 531-541.
38. Bigliardi P L. Pruritus - causes, diagnostics and treatment. Rev Med Suisse 2006: 26: 2: 1115-1118, 1120-1.
39. Vergnanini A L, Aoki V, Takaoka V, Madi J. Comparative effects of pimecrolimus cream vehicle and three commercially available moisturizers on skin hydration and transepidermal water loss. J Am Acad Dermatol 2007: 56 (Suppl. 2): AB60.
40. Endo K, Suzuki N, Yoshida O, Sato H, Fujikura Y. The barrier component and the driving force component of transepidermal water loss and their application to skin irritant tests. Skin Res Technol 2007: 13: 425-435.
41. Sugarman J L, Fluhr J W, Fowler A J, Bruckner T, Diepgen T L, Williams M L. The objective severity assessment of atopic dermatitis score: An objective measure using permeability barrier function and stratum corneum hydration with computer-assisted estimates for extent of disease. Arch Dermatol 2003: 139: 1417-1422.